LL-37 (13-37) (human) (trifluoroacetate salt)

Formulation: A solid

Formal Name: L-isoleucylglycyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-lysyl-L-arginyl-L-isoleucyl-L-valyl-L-glutaminyl-L-arginyl-L-isoleucyl-L-lysyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-arginyl-L-asparaginyl-L-leucyl-L-valyl-L-prolyl-L-arginyl-L-threonyl-L-α-glutamyl-L-serine, trifluoroacetate salt

Purity: ≥95%

Formula Markup: C137H232N42O36 • XCF3COOH

Notes: LL-37 (13-37) is an anticancer peptide fragment of LL-37 (Item No. 24461).{51691} It inhibits the ATPase activity of ATP-binding cassette transporter 2, subfamily G (ABCG2) when used at a concentration of 1 µM. LL-37 (13-37) induces cytotoxicity in wild-type SW620 cells and SW620 cells overexpressing P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1; IC50s = 25.5 and 27.3 µM, respectively), as well as wild-type MCF-7 cells, MCF-7 cells overexpressing ABCG2, and MCF-7 cells overexpressing multidrug resistance-associated protein 1 (MRP1; IC50s = 33.1, 31.8, and 31.1 µM, respectively). It potentiates cytotoxicity induced by mitoxantrone (Item No. 14842) in MCF-7 and HEK293 cells overexpressing ABCG2 when used at concentrations of 5 or 10 µM but not cytotoxicity induced by cisplatin (Item No. 13119) in HEK293 cells overexpressing ABCG2, paclitaxel (Item No. 10461) in SW620 cells overexpressing P-gp, or doxorubicin (Item No. 15007) in MCF-7 cells overexpressing MRP1 at the same concentrations. LL-37 (13-37) (10, 20, or 40 µM) decreases mitoxantrone drug efflux by, and increases mitoxantrone levels in, MCF-7 cells overexpressing ABCG2.

• SKU: CAY36949-5
• Manufacturer: Cayman Chemical
• Manufacturer SKU: 36949-5
• Package Unit: 5 mg
• Quantity Unit: STK